Banks Benefit From ...
Health Care: Drugs
Pharmacyclics Incorporated (PCYC: NASDAQ)
$23.23 3.43 | 17.34%
02/10/12 - 04:00 PM ET
3.94M / 823.60K
Vol / Avg. Vol:19.60 / 19.80
Open / Prev. Close:19.39 - 23.57
Today's Range:4.75 - 20.45
52 Wk Range:56.75%
Performance YTD:TheStreet Rating:
Portfolios with PCYC
- Portfolio NameUser Type
- ContributorStocks At New 52-Week Highs...
- ContributorStocks With Big Insider Buy...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks At New 52-Week Highs...
- ContributorFive Drug Stock Winners of ...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- ContributorRelative Strength Stocks 09...
- ContributorEarnings Short Squeeze Play...
Latest PCYC Headlines from TheStreet
- 5 Stocks Insiders Are Loading Up On 02.02.12 | 12:02 pm
- Insiders Trading CFX, MSFT, PCYC, HELE 01.27.12 | 11:01 am
- Celgene Now a Hep C Stock With Avila Buy 01.26.12 | 08:01 am
- Insiders Trading ZIOP, DEI, PCYC, XRAY 01.24.12 | 09:01 am
- Five Drug Stock Winners of 2011 12.19.11 | 08:12 am
- Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting 12.12.11 | 07:12 am
- Pharmacyclics Stock Falls On Unusually High Volume (PCYC) 12.09.11 | 11:12 am
- Insiders Trading PCYC, IT, PANL, ORLY 12.01.11 | 09:12 am
- 5 Stocks Poised for Breakouts 10.14.11 | 01:10 pm
- 5 Stocks to Watch: Hewlett-Packard, Cisco 09.13.11 | 07:09 am
Press Releases for PCYC
- Pharmacyclics Inc. Receives Issue Notice Of Significant Bruton's Tyrosine Kinase (BTK) Patent - PR Newswire 12.19.11 | 07:12 am
- Pharmacyclics® Announces Updated Results For BTK Inhibitor PCI-32765 For The Treatment Of Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma At American Society For Hematology (ASH) Annual Meeting - PR Newswire 12.13.11 | 11:12 am
- Pharmacyclics® Reports Interim Phase II Trial Results For BTK Inhibitor PCI-32765 In Mantle Cell Lymphoma At American Society Of Hematology (ASH) Annual Meeting - PR Newswire 12.12.11 | 02:12 pm
- Janssen Biotech, Inc. Announces Collaborative Development And Worldwide License Agreement For Investigational Anti-Cancer Drug, PCI-32765 - PR Newswire 12.08.11 | 04:12 pm
- Pharmacyclics Forms Pact To Develop And Commercialize PCI-32765 For Hematologic Cancers With Janssen Biotech, Inc. - PR Newswire 12.08.11 | 04:12 pm
- Pharmacyclics Appoints Chief Medical Officer Dr. Lori Anne Kunkel - PR Newswire 12.02.11 | 06:12 am
- Pharmacyclics Announces Collaboration With The National Cancer Institute To Develop Its Novel Btk Inhibitor, PCI-32765 In Hematologic Malignancies - PR Newswire 08.09.11 | 11:08 pm
- Pharmacyclics Announces Results Of Registered Direct Offering - PR Newswire 06.17.11 | 08:06 am
- Pharmacyclics Reports Recent Developments From Clinical Studies Of Its Btk Inhibitor PCI-32765 - PR Newswire 06.06.11 | 04:06 pm
- Pharmacyclics Achieves $7 Million Development Milestone For HDAC Inhibitor, PCI-24781 / S 78454 With Servier - PR Newswire 04.26.11 | 06:04 am
Partner Headlines for PCYC
- DUSA Pharmaceuticals Is A Small Gem - Seeking Alpha 12.23.11 | 02:12 pm
- YM's Positive Results Have Incyte Investors Worried - Seeking Alpha 12.15.11 | 09:12 am
- End-of-Day Market Summary for December 9, 2011 - Benzinga 12.09.11 | 04:12 pm
- Afternoon Movers; Positive Euro News - Benzinga 12.09.11 | 04:12 pm
- Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer - Seeking Alpha 10.25.11 | 08:10 am
- Emisphere: Crown Jewel In Oral B12 - Seeking Alpha 10.07.11 | 09:10 am
- Spectrum Pharmaceuticals: A Great Biotech Company For Around $8 - Seeking Alpha 08.26.11 | 05:08 am
- Puts Sold on Pharmacyclics Inc. (PCYC) - Benzinga 08.09.10 | 01:08 pm
- Protection Purchased on Pharmacyclics Inc. (PCYC) - Benzinga 07.06.10 | 04:07 pm
- Pharmacyclics lymphoma drug shows continued promise - Reuters 06.05.10 | 06:06 pm
